# OnCo record nct04579380 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04579380/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04579380", "NCT04579380" ;
  schema:name "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations"@en ;
  schema:description "A phase 2 trial of Tucatinib, Trastuzumab and Fulvestrant in endometrial cancer, cervical cancer, biliary tract cancer and non-small-cell lung cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04579380/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04579380> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2021-01-11" ;
  onco:cancers <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/her2-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/her2-tyrosine-kinase-inhibitors/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/fulvestrant/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct04579380-j-clin-oncol-2023/> .